Sikander Ailawadhi, Ivan Špička, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Meletios Athanasios Dimopoulos, Peter Rajnics, Vania Hungria, Maria del Rosario Custidiano, Gurdeep Parmar, Xavier P. Leleu, Tondre T. Buck, Jiri Minarik, Rick Zhang, Dorothee Semiond, Maya Stefanova-Urena, Philippe Moreau. "Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.7506